{{Rsnum
|rsid=1946468
|Gene=ADCY2
|Chromosome=5
|position=7617119
|Orientation=minus
|GMAF=0.4187
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADCY2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 46.0 | 40.7 | 13.3
| HCB | 18.2 | 55.5 | 26.3
| JPT | 25.7 | 50.4 | 23.9
| YRI | 34.0 | 49.0 | 17.0
| ASW | 36.8 | 56.1 | 7.0
| CHB | 18.2 | 55.5 | 26.3
| CHD | 20.2 | 50.5 | 29.4
| GIH | 18.8 | 50.5 | 30.7
| LWK | 35.5 | 54.5 | 10.0
| MEX | 24.1 | 50.0 | 25.9
| MKK | 26.9 | 52.6 | 20.5
| TSI | 40.2 | 46.1 | 13.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1946468
|Name_s=
|Gene_s=ADCY2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109317
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1946468
|overall_frequency_n=80
|overall_frequency_d=128
|overall_frequency=0.625
|n_genomes=50
|n_genomes_annotated=0
|n_haplomes=71
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}